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Introduction
Tendon disease and injuries have a huge impact on mor-
bidity and disability of patients, mainly as a result of the 
prolonged recuperation period. Due to the relative avascu-
lar nature of tendons, the regenerative potential is limited. 
This has significant impacts on the quality and speed of its 
healing. Hence, the latest research into the treatment of 
tendon disease and injury puts more emphasis on the appli-
cation of cell therapy to help overcome these treatment 
challenges.
Regenerative cell therapy is a subset of tissue engineer-
ing. Research data demonstrating the potential therapeutic 
use of exogenous cells within the discipline of tissue engi-
neering to treat tendon pathology prove to be quite promis-
ing.1 This review will focus on the use of cell therapy and 
its effectiveness as a form of treatment for tendon disease 
as well as injury. This would include the use of mesenchy-
mal stem cells (MSCs) and differentiated cells such as 
tenocyte and fibroblast.1
Background
Tendons are complex structures made up of tenocytes 
embedded within a dense extracellular matrix (ECM). 
Tenocytes synthesizes collagen (mostly type I) and other 
components of the ECM.2 The organization of the matrix 
is key to the function of tendons. Therefore, the tendon’s 
structural stability via its matrix organization will have 
significant effect on the functional outcome as a whole.
Tendons connect muscle to bone and enable forces gen-
erated by the muscle to transmit to bone causing move-
ment of the skeleton. The collagen fibers in tendon 
determine its material properties, giving it tensile strength 
and reducing stress exerted during muscle contraction.3 
Tendons are viscoelastic and can function as a shock 
absorber and as an elastic energy store. However, because 
of this function, tendons are constantly exposed to mechan-
ical stresses. Additionally, very high loads as much as 12.5 
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times the body weight can be placed on tendons during 
high impact activities such as jumping and weight-lift-
ing.4–7 This places enormous amounts of strain on tendons, 
especially in regions of repetitive loading, giving rise to an 
increased risk of injury to these tendon sites.
Tendon disease—defining terminology
Tendon disease (or tendinopathy) is hard to define particu-
larly due to poor understanding of the underlying patho-
physiology. The term “tendinosis” is used in histology to 
describe the pathological features seen in the ECM of the 
tendon,8 where there is failure of the matrix to adapt to 
stresses due to imbalance in synthesis and degeneration of 
the matrix.9–12 Many clinicians have adopted the term 
“tendinitis” or “tendonitis” to describe tendon disorders, 
indicating it is inflammatory in origin. However, with no 
histological evidence of this, it would be inaccurate to say 
so.13 Recent histopathological studies have shown that the 
presence of degeneration occurs before spontaneous rup-
ture, and the inflammatory phase is not typically seen until 
rupture occurs.14,15 This indicates that inflammation is not 
causative but as a result of the injury. Tendon disease or 
tendinopathy describes a process of degeneration rather 
than inflammation. Sharma and Maffulli16 recommended 
the use of the term “tendinopathy” to accurately describe 
tendon disease or disorders instead (see Table 1).
Tendon injury
Tendon injuries range from a spectrum of acute tendon 
rupture to chronic degenerative tendinopathy. Tendons 
have a lower oxygen consumption compared to other tis-
sues allowing tendons to function for longer periods of 
time without fatiguing.19 Studies using laser Doppler have 
shown compromised blood flow at junctional zones, sites 
of torsion, friction, and compression.20 Unsurprisingly, 
injuries often occur at these sites of strain, and the limited 
perfusion to these areas would undoubtedly compromise 
the healing process. As a result, recovery times of tendon 
damage can take up to 6 months with the first line treat-
ment.9 The prevalence of tendon injuries is approximately 
14.2% in elite athletes21 and also accounts for about 
30%−;50% of musculoskeletal injuries affecting an esti-
mate of 100 million people globally each year.22 With 
potentially extended recuperation period, this will undoubt-
edly have a significant impact on the clinical management 
and financial implications of tendon injuries.
It is particularly important to understand the etiology of 
a disease so that patients can be treated correctly. However, 
the exact causes of such tendon rupture are still relatively 
unclear.23 It is convenient to assume that such injuries are 
based entirely on mechanical damage, but this is not 
always true. There has been more research into the under-
lying pathology of tendon injury. Many studies have 
shown that spontaneous tendon rupture does not just occur 
acutely due to mechanical insult but over time with signs 
of an ongoing degeneration process.14,15 Preexisting degen-
eration has been implicated as a risk factor for acute ten-
don rupture due to reduced tensile strength caused by 
repetitive overstraining.16 Common injury sites are the 
Achilles and patellar tendons, rotator cuff complex, and 
finger flexors, demonstrating a level of anatomical influ-
ence over injury as well.
Tendon healing
Tendon healing is a complex process influenced by several 
factors. It is mainly described in distinctive stages: inflam-
mation, proliferation, and remodeling.16,24 The inflamma-
tory stage is characterized by an acute inflammatory 
response with infiltration of extrinsic cells such as fibro-
blast, neutrophils, and macrophages. There is also synthe-
sis of chemotactic agents to encourage the process of 
cellular migration as well as release of bioactive factors to 
promote angiogenesis.25 The proliferative phase begins 
after 4–7 days of inflammatory phase. This is mainly a 
reparative process where a substantial increase in synthe-
sis of types I and III collagen is observed. The granulation 
tissue forms a scar-like structure around the wound site 
Table 1. Defining tendon disease terminologies8.
Terminology Definition Ref.
Tendinopathy Umbrella term for tendon disease. The recommended 
term to clinically describe tendon disease or disorders.
Sharma and Maffulli16
Tendinosis Histological description of degenerative features seen in 
tendon disease.
Puddu et al.,8 Khan et al.,9 Leadbetter,10 
Riley et al.,11 and Selvanetti et al.12
Tendinitis/tendonitis Indicates inflammatory process in tendon disease which 
is thought to be an inaccurate clinical terminology of 
degenerative tendon disease.
Maffulli et al.13 and Khan et al.17
Tendon rupture Torn tendon causing discontinuity of the tendon 
structure as a whole. Can be caused by trauma or end 
result of ongoing degenerative changes.
Kannus and Józsa14 and Tallon et al.15
Source: adapted from Wang et al.18
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and contains the components which make up the ECM. At 
this point, the immature cells of the ECM would synthe-
size mainly type III collagen in a haphazard randomized 
manner.26 The final remodeling stage commences at 
6–8 weeks after injury. It is characterized by a decrease in 
cellularity and reorganization of the collagen architecture 
where type III collagen will be replaced with type I colla-
gen. As the scar tissue matures, the collagen units interact 
in such a way that they lead to greater tendon stiffness and 
tensile strength.25
Despite the remodeling, healed tendons never fully 
restore the ECM structure and material properties to match 
those of normal intact tendons.16,27 This can be due to a 
number of reason such as poor vascular supply to tendons 
which leads to poor scar tissue formation which is then 
further exacerbated by the inevitable biomechanics burden 
to healing tendons. All of these factors compromise heal-
ing which in turn reduces efficiency of tendon perfor-
mance.16 In addition, studies on tendinopathic and ruptured 
Achilles tendons demonstrated abnormal healing response 
where the healing tenocytes showed a reduction in type I 
collagen and a significant increase in type III collagen.28 
This resulted in reduced tensile strength due to fewer num-
ber of cross links in type III collagen as compared to type 
I. This property is thought to be responsible for the bio-
logical inferiority of the repaired tissue’s strength and poor 
healing of tendons.29
Current treatments for tendon 
disease
Managing tendon disease is clinically challenging, as the 
exact pathophysiology of tendon disease is still unclear 
and treatments for tendon disease are inconsistent and 
highly variable in many centers. Therefore, most treatment 
programs do not yield very high success rates in general.
There have been many proposed therapeutic strategies 
for treatment of tendon disease which can be broadly clas-
sified into surgical and nonsurgical. Surgical treatments 
are more likely to be advocated for acute tendon injury or 
rupture where damaged tendons are sutured together with 
or without the use of autografts, allografts, or prosthetic 
devices to close the rupture site. For chronic tendinopa-
thies, surgery is often only used as the last resort after all 
other treatment options have been exhausted. Where con-
servative management is indicated in acute tendon inju-
ries, the affected tendon will be placed in a cast and the 
repair process will be entirely dependent on the body’s 
natural healing ability.
Several nonsurgical therapies have also been advo-
cated, such as the use of steroidal and nonsteroid anti-
inflammatory medication in short-term treatment of 
tendinopathies.30 Active physiotherapy via eccentric exer-
cises has been shown to be effective in supporting rehabili-
tation.31,32 There are also several commercial treatment 
modalities in the market such as therapeutic ultrasound, 
inotophoresis, phonophoresis, and low-level laser. All but 
ultrasound treatment, which has been shown to have posi-
tive effect in treatment of lateral epicondylitis, has no firm 
evidence to support its widespread use clinically. More 
research into its therapeutic benefits is required.30 Other 
available alternative therapies include topical glyceryl 
trinitrite, therapeutic hyperthermia, injectables for scleros-
ing treatment, and extracorporeal shock wave therapy. 
Some have shown promising effect on treatment of tendi-
nopathy, but similar to the other proposed therapies above, 
there is currently very little evidence in literature to fully 
support its application. Going into detail of all these clini-
cal therapies would go beyond the scope of this article. 
One thing is clear; there is a need for more well-designed 
randomized control trials to accurately prove its clinical 
effectiveness. Despite all these available treatment options, 
injured tendons still never fully restore to its original con-
dition.16,25,27 As a result, current research has concentrated 
much of its efforts into regenerating tendons to as close to 
its original structure and function as possible via cell-
based therapies.
Cell therapy in tendon disease
Rationale
During the natural healing process of tendons, fibroblastic 
cells have been observed at the site of repair and are known 
to play a role in tendon regeneration by synthesizing col-
lagen.16 It has been widely accepted that these cells arise 
from undifferentiated MSCs. However, the source of these 
MSCs, whether they originate from the surrounding tis-
sues or via the blood supply from the bone marrow, still 
remains controversial.1 The critical question is whether 
there are sufficient cells recruited into the repair site in the 
first instance to generate enough healing potential. This 
uncertainty has led to research around the application of 
exogenous cells to facilitate tendon healing. This is the 
fundamental principle of cell therapy.
Cell therapy and tissue engineering techniques
To date, there are various techniques that fall under the 
umbrella of cell therapy. These are as follows:33
1. Cell replacement therapy where existing cells with 
or without gene defects or mutations are replaced 
by healthy donor cells via local infiltration of stem 
cells to site of injury;
2. Tissue engineering technique using a three-dimen-
sional scaffold incorporated with cells to replace 
tendon tissues in vivo;
3. Use of stem cells as cytokine and growth factor 
pumps to stimulate growth and repair of tendons.
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Literature search
We performed a comprehensive literature for the above 
subtopics of cell therapy to obtain animal studies pertain-
ing to each field. Our search strategy for available litera-
ture made use of MEDLINE via PubMed search engine 
using the various combinations following terminologies 
with relevance to the topic sought: “tendon,” “tendon 
injury,” “tendon repair,” “tendon healing,” “cell therapy,” 
“stem cell,” “mesenchymal cell,” “tenocyte,” “fibroblast,” 
“bone marrow–derived,” “adipose-derived cell,” “tendi-
nopathy,” “tendinosis,” “tissue engineering,” “regenera-
tion,” “scaffold” (and use of commercial names), “growth 
factors” (and specific growth factors), “cytokines,” “gene 
therapy,” “gene transfer,” and “biological augmentation.” 
Articles were screen first by title and then by their abstract 
to see whether they provided relevant information. 
Reference list from systematic review articles was also 
used to source out relevant articles not already included in 
the existing list of articles found via PubMed.
Cell replacement therapy
Cell replacement therapy involves implanting healthy cells 
into areas of tendon loss or severe degeneration to opti-
mize healing of tendons. The ideal cell type should be easy 
to isolate and should have the ability to proliferate rapidly 
in vitro.34 Once implanted, they should not induce immu-
nological response from the host. Obtaining cells to pro-
mote such healing can come from various sources: 
embryonic stem cells, adult stem cells, and autologous dif-
ferentiated cells.
Stem cells are known to regenerate and replace damaged 
and diseased tissues in vivo. There are two types of stem 
cells that can be used for cell therapy—embryonic and adult 
stem cells. Due to the difficulty in controlling differentia-
tion, potential tumorigenesis, and ethical controversy sur-
rounding the use of embryonic stem cells, adult stem cells 
are a preferred source for regenerative purposes.35 Adult 
stem cells reside in adult tissues and are relatively easy to 
isolate. Despite the fact that they have lesser proliferative 
capacity to that of embryonic stem cells, research has shown 
that under the right conditions, they are relatively easy to 
culture and expand.36–41 In vitro and in vivo assays have 
identified adult MSCs which take multipotency lineages 
capable of differentiating into specialized tissue cells such 
as bone, cartilage, muscle, fat, tendon, and ligament.36,38,41,42 
Hence, MSCs can be extracted from bone marrow and other 
sources such as adipose tissue, synovium, muscle, tendon, 
ligament, periosteum, subcutaneous scalp tissue, circulating 
peripheral blood, and umbilical cord blood.43,44 Given the 
abundant source of MSCs in the body combined with its 
potential regenerative effects, MSCs prove to be a powerful 
tool for cell therapy in tendon disease.38,39,45,46 This is evi-
dent from the large amount of published literature discuss-
ing the use of MSCs over other cell types.
Several studies have also demonstrated the successful 
use of autologous differentiated cells, such as tenocytes 
and fibroblasts, either directly injected into tendon 
defects or seeded in constructs for culture and implanta-
tion into tendon defects of animal models. Histological 
and biomechanical assessment demonstrated success-
fully bridging of gaps in the tendon with the new tendon 
construct closely resembling that of the native form in 
terms of structure and tensile strength.47–49 This has 
promising implications, but there are a number of con-
cerns such as the availability of donor sites for cell har-
vest, the long in vitro culture expansion times, and donor 
site morbidity which restrict the practicality of such 
autologous cell-based techniques.34
More recently, scientists have discovered another prom-
ising cell source in the form of induced pluripotent stem 
cells (iPSCs). This breakthrough method, first discovered 
by Takahashi and Yamanaka50 in 2006, consists of “repro-
gramming” differentiated cells with genetic modifications 
in laboratory conditions to become more pluripotent in 
nature, resembling features similar to embryonic stem 
cells. This has led to new avenues of cell therapy research 
and may solve the problem of cell source and abundance in 
tissue engineering as well as the ethical issues surrounding 
the use of embryonic stem cells. However, due to problems 
with tumorigenesis and potential problems with the use of 
viruses to induce pluripotency, there is still further work 
required in this field to improve the efficacy and safety 
issues surrounding the use of iPSCs in the clinical 
setting.51
For clinical application of cell therapy in tendon dis-
ease, it is important to acknowledge the fundamental dif-
ferences in the treatment of tendinopathies and acute 
tendon ruptures. They are essentially two separate physio-
logical and biomechanical events. In acute tendon rupture, 
there is either partial or complete loss of tissue interface. 
Due to the inability for tendon to regenerate, the applica-
tion of use of cell therapy may be more relevant. In tendon 
ruptures, the use of scaffolds combined with cell therapy is 
possible but not in tendinopathies unless the degenerated 
section is surgically excised and replaced.
In animal studies, the use of MSCs has been applied to 
horse tendon disease and defects with encouraging 
results.52–58 Tendon injuries are very common in horses, 
and because of biological similarity of their superficial 
digital flexor tendon to that of the Achilles tendon in 
humans, success in use of MSCs repair of tendons in horse 
can have significant implications on the clinical applica-
tion in humans.59–61 Table 2 summarizes the results from 
animal model cell therapy studies which have been pub-
lished. We performed a literature search to look for animal 
studies using cell therapy interventions only. Any study 
that included any other intervention such as scaffold, spe-
cific growth factors, or gene therapy was not included here 
but will be discussed later in this article.
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Table 2. Animal models using cell replacement therapy.
Study (author/
year/ref.)
Model (n number 
where available)
Type/site of study Treatment type Results
Godwin et al. 
(2012)62
Horses (141) Naturally occurring 
SDFT tendinopathy 
diagnosed with 
ultrasound evidence
BMMSC direct 
injection
Lower reinjury rates compared to national 
published rates for racehorses
Emrani and 
Davies (2011)63
Nude rats (48) Collagenase-induced 
tendinopathy to the 
Achilles tendon
Human umbilical 
cord perivascular 
cells direct 
injection
Improvement in collagen organization and 
increase in tendon tensile strength and 
stiffness by 30 days post injury
Chen et al. 
(2011)64
Rabbits (44) Tendinopathy induced 
by type I collagenase 
injection to the Achilles 
tendon
Autologous 
tenocytes direct 
injection
Autologous tenocytes therapy improved 
type I collagen expression in repaired 
tendon but did not affect type III collagen 
and secreted protein, acidic and rich in 
cysteine expression
Watts et al. 
(2011)58
Horses (8) Collagenase gel-physical 
defect model in the mid-
metacarpal region of the 
SDFT
fdESC direct 
injection
Histological improvement of tissue 
architecture and ultrasound in the treated 
tendons. No differences in tendon 
matrix–specific gene expression or total 
proteoglycan, collagen, or DNA of tendon 
lesions between groups
De Mattos 
Carvalho et al. 
(2011)57
Horses (8) Collagenase-induced 
tendinopathy to SDFT
AdMSC Histological improvement in tendon of 
ECM; no differences between the groups 
regarding the clinical and ultrasonographic 
analyses
Crovace et al. 
(2010)56
Horses (6) Collagenase-induced 
tendinopathy to SDFT
BMSC and 
BMMNC
Qualitatively similar healing improvement 
of tendon extracellular matrix 
histologically
Nixon et al. 
(2008)55
Horses (8) Collagenase-induced 
tendinopathy to SDFT
Adipose-derived 
nucleated cell
Little difference in biochemical and 
molecular differences; tendons appeared 
architecturally improved
Barreira et al. 
(2008)54
Horses (6) Collagenase-induced 
tendinopathy to SDFT
BMMSC Cellular therapy with the mononuclear 
fraction of bone marrow has accelerated 
tendon repair at 48 days after treatment
Lacitignola et al. 
(2008)53
Horses (6) 
(experimental); 
horses (20) 
(clinical)
Experimental study: 
Collagenase-induced 
tendinopathy to 
SDFT; clinical study: 
spontaneous lesions of 
the flexor tendons or the 
suspensory ligament
Experimental: 
BMMSC, 
BMMNC, and 
fibrin glue; 
clinical: BMMNCs 
and fibrin glue 
suspension
Experimental: improved ECM with cBMSC 
and BMMNCs. Nil improvement with 
fibrin glue over placebo; clinical: improved 
clinical characteristics via ultrasound and 
outcome (return to racing)
Crovace et al. 
(2008)65
Sheep (6) Collagenase-induced 
tendinopathy of the 
Achilles tendon
BMMSC, BMMNC 
with fibrin glue, 
saline, or control 
solution
Improved histological appearance and 
immunohistochemistry analysis over 
control
Ni et al. 
(2013)66
Nude mice Patellar tendon window 
defect
Scaffold-free 
tendon tissue 
produced by 
tendon-derived 
stem cell
Neo-tendon formation in a rat patellar 
tendon window injury model
Chen et al. 
(2012)67
Rat (96) Partial Achilles tendon 
window defect
PRP, TdSC, and 
combination of 
PRP + TdSC
Combination of TSCs and PRP has 
synergistic effects on tendon and loaded 
conditions improved tendon healing
Uysal et al. 
(2012)68
Rabbit (6) Achilles tendon window 
defect
PRP and 
autologous AdSC
Enhanced tendon healing with increased 
tensile strength
(Continued)
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Scaffolds
A study by Wakitani et al.72 in 1994 showed that when 
cells are cultured in a free-floating collagen gel, they grew 
in a disorganized manner, eventually deforming the gel 
structure. But when two fixed posts were placed in the col-
lagen gel, cells and collagen fibers aligned along the axis 
of contraction between the two posts, demonstrating the 
need for additional mechanical support such as suturing in 
scaffold constructs.72,73 Therefore, cells need a suitable 
scaffold to provide mechanical support for three-dimen-
sional growth as well as a vector for implantation. One 
early in vivo study by Young et al. in 1998 delivered cul-
tured MSCs from rabbit bone marrow in collagen type I 
gel to large tendon defects in rabbit Achilles tendons. This 
study demonstrated significant improvement to the biome-
chanics and structure post injury as compared to controls.74 
Juncosa-Melvin et al.75,76 later showed that the introduc-
tion of mechanical stimulation to the collagen scaffolds 
increased the gene expression of type I and type III colla-
gen which improved the biomechanical properties of the 
construct in vivo. This demonstrates that tissue engineered 
and fabricated scaffold combined with the use of stem cell 
can successfully restore mechanical integrity and biologi-
cal healing of the torn and ruptured tendon. Hence, using 
tissue engineered scaffolds to treat tendon injuries can 
offer significant therapeutic potential.
The fabrication of tendon scaffolds requires the follow-
ing characteristics in order to yield success in vivo: (1) 
biocompatible and biodegradable to be able to provide a 
short-term stability of the cell transplant and allow for 
integration into host tissue with higher porosity for cell 
attachment. (2) They should match the mechanical proper-
ties of the host tissue and respond to its kinetics. (3) Fibril 
alignment influencing the architecture of the scaffold is 
critically important to enable functional transmission of 
force across the tendon.77–79 Problems with scaffold design 
that researchers often face with are usually due to any of 
the above failings. This results in decreased biocompatibil-
ity and mismatched degradation kinetics which leads to the 
inability of scaffolds to fully integrate into host tissue. 
Where there are differences in biomechanical properties to 
native tendon, this can cause incongruous forces to be 
transmitted across the tendon and scaffold, increasing the 
failure rate of repairs. In addition, due to lack of necessary 
bioactive properties within the scaffold, this may result in 
decreased capacity to induce cell adhesion and 
proliferation.80
Scaffolds that are off the shelf have inherent advantages 
over traditional tendon repair/grafts. These are often syn-
thetically made. However, synthetic materials can also 
carry an increased risk of infection in the long term.81
Tendon scaffolds are divided into two major categories: 
natural and synthetic polymers. Synthetic polymers have 
equivalent biomechanics and physical properties as ten-
dons, but the main drawbacks are graft rejection, inflam-
mation reaction, and cell toxicity.
Synthetic polymers such as poly(lactide-co-glycolide) 
(PLGA), polyglycolide (PGA), and polylactide (PLA) are 
Food and Drug Administration (FDA) approved and are 
widely used in tendon tissue engineering. Advantages of 
these polymers are the easily engineered and predictable 
biomechanics they inherently possess as well as the fact 
that electrospun alignment of these fibers can easily mimic 
native tendon. Combination of these polymers with bone 
marrow stromal cells (BMSCs), tenocytes, and growth 
factors has been shown to significantly improve repaired 
tendon function in vivo and in vitro.82–85 Moshiri et al. 
were able to repair large tendon gap of 2 cm in the Achilles 
tendon in a rabbit model using synthetically derived 
Study (author/
year/ref.)
Model (n number 
where available)
Type/site of study Treatment type Results
Lee et al. 
(2011)69
Rat Achilles tendon window 
defect
BMMSC Cellular differentiation into tenocytes and 
formation of tendon-like tissue
Guest et al. 
(2010)52
Horse (8) Superficial digital flexor 
tendon window defect
ESC and 
autologous 
mesenchymal 
stromal cells
ESC survived and migrated to the damaged 
tendon but not mesenchymal stromal cells
Nourissat et al. 
(2010)70
Rat (142) Achilles tendon window 
defect
MSC injected in 
the site of the 
injury
Better healing as compared to control 
group
Chen et al. 
(2009)71
Rat (36) Patellar tendon window 
defect
hESC 
differentiated into 
MSC
Better structural and mechanical 
properties than control
BMMSC: bone marrow mesenchymal stem cells; fdESC: fetal-derived embryonic-like stem cells; BMSC: bone marrow stromal cell; BMMNC: bone 
marrow mononucleated cell; BMMSC: bone marrow mesenchymal cell; AdMSC: adipose tissue–derived MSC; SDFT: superficial digital flexor tendon; 
ECM: extracellular matrix; ESCs: embryonic stem cells; hESC: human embryonic stem cells; cBMSC: cultured bone marrow mesenchymal cell; PRP: 
platelet-rich plasma; TdSC: tendon-derived stem cell; MSC: mesenchymal stem cell.
Table 1. (Continued)
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electrospun collagen. Results show that it restored 50% of 
its biomechanics and cellular properties within the neoten-
don by the end of 3 months.86
Natural polymers have the advantage of being biocom-
patible and can possess native biological ECM such as col-
lagen. Collagen is a highly conserved protein in the tendon 
with almost 60% of tendon being made up of it; of which, 
95% is type 1 collagen.77,87,88 Collagen itself does not 
exhibit strong mechanical properties, but in combination 
with other polymers and/or with MSCs, this can increase its 
biomechanics as well as provide a suitable environment for 
stem cell differentiation to the tenocytes within the scaffold 
matrix.89,90 Sawadkar et al.91 demonstrated that by sharing 
suture tension away from tissue engineered collagen graft, 
biomechanics of the repair to the clinical standard in a ten-
don defect of 2 cm increased. Chitosan–hyaluronan, algi-
nate–chitosan hybrid polymer, and chitosan scaffolds have 
also shown significant collagen type I synthesis with cel-
lular affinity and ECM production similar to that of living 
tendons.92–95 Funakoshi et al.96 successfully repaired 
10-mm rotator cuff defect by chitin nonwoven fabric acel-
lular matrix after 12 weeks infiltration of cells with colla-
gen fibril alignment. Bioengineered tendon graft fabricated 
from porcine small intestine submucosa (SIS) also demon-
strated the ability to repair and strengthen flexor tendon 
defect by collagen deposition and increase in the transform-
ing growth factor-β (TGF-β) levels in the rabbit model.97 
Another approach to maintain mechanical integrity of the 
natural polymer is through the use of decellularized tendon 
scaffolds. This is an attractive technique as it retains the 
tendon’s normal tissue architecture. Several research 
groups are now focusing on using decellurized tendon to 
treat tendon defects.98,99 A recent study used decellularized 
porcine tendon which was recellularized with human ham-
string tendon, and the results showed successful tenocyte 
and glycosaminoglycan (GAG) recovery.100 This is a very 
promising finding which would certainly pave the way for 
further use of xenogeneic material in humans which in 
itself would have a distinctive advantage over allogeneic 
means due to the more abundant supply of tissue available 
for transplant. However, effective decellularization of tis-
sue itself is a challenging process, and further research into 
the methodology is still required to refine it for clinical use.
Engineered scaffold can have therapeutic complica-
tions, and unfortunately, there is no gold standard for the 
use in tendon repair. Some researchers propose the use of 
scaffold-free arrangements or cell-produced constructs as 
potential alternatives. A study has shown that scaffold-free 
aligned tendon structure can be produced by using rat 
Achilles tendon cells to produce neotendon with satisfac-
tory biomechanics properties.101 In another study, tendon 
constructs were produced by tendon-derived stem cells 
which demonstrated the ability to repair rat patellar tendon 
in window defects at 12 weeks.66
However, with so many different scaffolds advocated in 
literature, it is difficult to see which scaffold truly champions 
over the rest. To assist with this comparison, it would be nec-
essary for future research to conduct larger animal studies in 
order to produce more statistically significant results for the 
ideal scaffold to be appreciated. Table 3 summarizes the list 
of published animal model studies where scaffolds were 
used in combination with cell therapy.
Tissue engineering with cell therapy and growth 
factors
Cytokines and growth factors are signaling molecules 
involved in cell migration, proliferation, differentiation, 
and matrix synthesis. They play a key role in stimulation 
and regulation of stem cell differentiation, hence influenc-
ing the process of wound healing as a whole.117 During 
tendon repair, these factors are expressed by cells, such as 
fibroblast and inflammatory cells, to activate specific cell 
signaling pathways leading to transcription of regulatory 
genes. This stimulates the appropriate cells to migrate and 
proliferate or to synthesize collagen, matrix components, 
and angiogenesis as part of the reparative phase in tendon 
repair.25 The identification of these growth factors was 
shown in rat and human models which demonstrated the 
release of growth factors with different phases in tendon 
healing and showed how these factors interacted with one 
another.118–120 The key growth factors involved and their 
role in tendon healing are shown in Figure 1.
Several studies have taken this concept to the laboratory 
by determining the biological significance of growth factors 
in regenerating tendons in vitro and in vivo. Insulin-like 
growth factor 1 (IGF-1), which is expressed in large amounts 
during the inflammatory phase of healing, has been shown 
to stimulate migration and proliferation of many different 
cells including fibroblast, tenocytes, and inflammatory cells 
such as neutrophils and macrophages.122 It can also stimu-
late collagen production and matrix synthesis.123 In in vivo 
studies, IGF-1 has been shown to improve the rate of heal-
ing in rat Achilles tendon model.124 TGF-β has been shown 
to be active in practically all stages of tendon healing.125 It 
exerts a stronger effect on matrix synthesis and collagen 
production than on cell chemotaxis and proliferation. Klein 
et al.126 showed that TGF-β isoforms significantly increased 
collagen types I and III in cultured rabbit sheath in vitro. 
Platelet-derived growth factor (PDGF) assists in the synthe-
sis with other growth factors such as IGF-1 in the initial 
stages of tendon repair.127 It is also involved in cell prolif-
eration and overall collagen synthesis; an in vitro study 
demonstrated 300% increase in collagen synthesis with 
PDGF stimulus.128 Basic fibroblast growth factor (bFGF) is 
a potent factor in angiogenesis and cell migration and prolif-
eration.129 In vitro and in vivo study models show signifi-
cant effects on wound healing and acceleration of the rate of 
tendon healing, but this is only evident in the initial stages of 
healing.130,131 Vascular endothelial growth factor (VEGF) is 
another crucial angiogenic factor responsible for producing 
vascularity at the site of repair of tendons. Therefore, it 
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plays an important role in tendon healing. Zhang et al.132 
showed a significant increase in tensile strength of 
postoperative tendons treated with VEGF in rat Achilles 
tendons compared to controls. Bone morphogenetic protein 
Table 3. Animal models using cell therapy and scaffolds.
Study (author/year/ref.) Model (n number 
where available)
Site of study Treatment type Results
Schmitt et al. (2013)102 Athymic rats  
(14)
Achilles tendon 
window defect
Decellularized human 
flexor tendon seeded with 
human AdSC
Cell invasion at repair site. 
No increase in type III 
collagen
Webb et al. (2013)103 Rats (20) Achilles tendon 
window defect
PHBHHx 
scaffold ± collagen 
gel ± tenocytes
Successful use of PHBHHx 
scaffolds in vivo
Ni et al. (2012)104 Rat (38) Patellar tendon 
window defect
TdSC with fibrin glue 
constructs
TdSCs significantly enhanced 
tendon healing by the increase 
in collagen production and 
mechanical strength
Yokoya et al. (2012)105 Rabbit (34) Infraspinatus tendon 
window defect
PGA and MSC Better tensile strength in MSC 
group than in the PGA and 
control
Omae et al. (2012)106 Rabbit Patellar tendon 
window defect
Decellularized tendon 
seeded with BMSC
Increased gene expression of 
tendon-specific genes
Hankemeier et al. 
(2009)107
Rat (96) Patellar tendon 
window defect
Human BMSC in a fibrin 
matrix
Stimulated tendon healing 
with increase in the collagen 
fibril diameter
Gulotta et al. (2009)108 Rat (98) Rotator cuff tendon 
defect
MSC in a fibrin carrier No improvement in the 
structure, composition, or 
strength of the healing tendon
Ju et al. (2008)109 Rats (19) Bone tunnel in the 
tibial plateau
MSC in Achilles tendon 
grafts
Implanted tendon attached to 
the bone
Hankemeier et al. 
(2007)110
Rat (48) Patellar tendon 
window defect
Human BMSC and liquid 
fibrin glue injected at the 
site
Appearance of dense collagen 
fibers and spindle-shaped cells
Liu et al. (2006)49 Pig (45) Defect flexor digital 
superficial tendon 
window defect
Autologous dermal 
fibroblasts and tenocytes 
in a PGA scaffold
No type III collagen, neotissue 
mechanical weak, disoriented
Juncosa-Melvin et al. 
(2006)75
Rabbit (10) Patellar tendon 
window defect
MSC with collagen sponge Mechanical stimulation 
improves tendon repair
Funakoshi et al. (2005)111 Rabbit (48) Infraspinatus tendon 
window defect
Seeded fibroblast in a 
chitosan-based hyaluronan 
hybrid polymer fibers
Tensile strength and tangent 
modulus significantly 
improved
Ouyang et al. (2004)112 Rabbit (14) Patellar tendon 
window defect
BMSC in window defect 
with fibrin glue
Changed cell morphology, and 
BMSC were alive
Ouyang et al. (2003)113 Rabbit (19) Achilles tendon 
window defect
PLGA loaded with BMSC Potential to regenerate 
and repair gap defect with 
increased tensile strength
Awad et al. (2003)114 Rabbit (94) Patellar tendon 
window defect
Collagen gel with MSC Increased biomechanics and 
MSC concentration
Ouyang et al. (2002)115 Rabbit (16) Achilles tendon 
window defect
BMSC in a PLGA scaffold Improved tendon repair
Cao et al. (2002)47 Hen (40) Flexor digitorum 
profundus tendon 
defect
PGA wrapped in a 
intestinal submucosa 
membrane with tenocytes
Bridge the tendon defect
Awad et al. (1999)116 Rabbit (18) Patellar tendon 
window defect
MSC in type I collagen gel Improved biomechanics but 
not microstructure
Young et al. (1998)74 Rabbit (53) Achilles tendon 
window defect
BMSC seeded in collagen 
constructs
Collagen fibril aligned, 
improved tendon defect
AdSC: adipose-derived stem cells; PHBHHx: poly(3-hydroxybutyrate-co-3-hydroxyhexanoate); TdSC: tendon-derived stem cell; PGA: polyglycolic 
acid; MSC: mesenchymal stem cell; BMSC: bone marrow stromal cell; BMMSC: bone marrow–derived mesenchymal stem cell; PLGA: poly(lactide-co-
glycolide).
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(BMP) is known to promote bone formation and can also 
produce tendon-like connective tissue when delivered to an 
ectopic area.25 There are various forms of BMP: BMP-12, 
-13, and -14 are most commonly found in human tendons.133 
It is also known as growth differentiation factor (GDP)-7, 
GDP-6, and GDP-5 or cartilage-derived morphogenetic 
protein (CDMP)-3, CDMP-2, and CDMP-1 in other litera-
tures.25 In vivo studies have shown that the delivery of BMP 
can improve tensile strength of transected tendons.134–137
An increasing number of studies have described the use 
of MSCs for growth factor application via gene transfer 
techniques.35 MSCs have been shown to preferentially sur-
vive and proliferate in regenerative tissues when injected 
into the circulation.40 This property can be exploited by 
using MSCs as vectors for gene therapy (see Table 4). 
Transduced MSCs are genetically modified by viral vec-
tors such as adenovirus and retrovirus to house genes that 
specifically express growth factors known to promote ten-
don formation. They are injected into the host and are tar-
geted to site of tendon healing. They then release a steady 
production of growth factors which are known to aid ten-
don regeneration by promoting cell proliferation and 
matrix synthesis.126,137,146,147 This has been shown to 
improve the structural repair of tendinopathy animal mod-
els when transgene MSCs expressing IGF-1 were com-
pared to control groups treated with just MSCs alone.141 In 
vitro studies have also shown increase in growth factor 
expression which in some cases have demonstrated 
increase in abundance of type I collagen synthesis. But this 
was not always consistent among all the studies as there 
are variability in the use of different types of growth fac-
tors and viral carriers.142–145 The use of tendon fibroblast 
transfected with IGF-1 via retrovirus in one study showed 
improved tendon repair in in vivo rat model.128 In separate 
study, using adenovirus BMP-13 gene transduced bone 
marrow mesenchymal stem cells (BMMSC) did not show 
any improvement in rotator cuff repair rat model.139 
However, it appears that combining growth factors such as 
PDGF-β and IGF-1 into genetically modified fibroblast 
held in a synthetic scaffold showed improvement in cell 
proliferation and collagen production in vitro and acceler-
ate rate of repair in vivo.128 Therefore, much more research 
is still required in order to determine the appropriate 
growth factor combination and timing of growth factor 
release from transduced cells which will produce the most 
effective tendon repair model in vivo.
The same concept can also be applied for replacing cells 
with genetic defects, but its relevance to tendon disease has 
not yet been established. Due to its labor intensive process, 
this technique can only be recommended for treatment of 
degenerative processes instead of acute tendon injuries.
Current translational research: going into 
clinical trials
As animal models establish more evidence in the benefits 
of cell therapy in tendon disease, the number of clinical 
trials using MSCs is growing. Performing a literature 
search via PubMed and clinicaltrials.gov using combina-
tions of terms “tendon,” “epicondylitis,” “tennis elbow,” 
“rotator cuff,” “tendinopathy,” “Achilles tendon,” “patel-
lar tendon” with “stem cell,” “autologous cell,” “cell ther-
apy,” “cell transplantation,” “tenocyte,” “fibroblast” and 
“humans,” “adult,” “clinical,” “treatment outcome,” and 
“double-blind method” yielded five published articles 
demonstrating the use of cell therapy in human trials (see 
Table 5).
Four of the five trials had tendinopathy as the primary 
pathology of clinical concern. Wang et al. and Connell et 
al. carried out similar studies with lateral epicondylitis 
patients where patellar tendon-derived autologous teno-
cyte and skin-derived fibroblast, respectively, were infil-
trated into the affected area. Both studies demonstrated 
therapeutic benefit from this treatment in the form of a 
patient scoring system at follow-up. In addition, both stud-
ies also showed objective improvement to patient’s imag-
ing appearances on magnetic resonance imaging (MRI) at 
12 months for Wang et al.148 and ultrasound scan (USS) at 
Inflammatory phase Proliferative phase Remodeling phase
Fibroblast and inflammatory 
cells chemotaxis:
IGF-1, TGF-β
Stimulates and regulates 
expression of other growth 
factors: PDGF
Promotes angiogenesis:
VEGF, bFGF
Cell proliferation: 
IGF-1, PDGF, TGF-β, bFGF, 
BMP -12, -13, -14
Collagen synthesis and ECM 
components:
IGF-1, PDGF, bFGF, TGF-β
Cell-matrix interaction: 
TGF-β, bFGF
ECM remodeling: IGF-1
Termination of cell 
proliferation:
TGF-β
Collagen Type I synthesis: 
TGF-β, BMP -12, -13, -14
Figure 1. Expression of growth factor during tendon healing phases.25,117,121
IGF-1: insulin-like growth factor 1; TGF-β: transforming growth factor β; PDGF: platelet-derived growth factor; bFGF: basic fibroblast growth factor; 
VEGF: vascular endothelial growth factor; BMP: bone morphogenetic protein; ECM: extracellular matrix.
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6 months for Connell et al.149 However, with no compara-
tive group, it is hard to measure these improvements 
statistically.
In the trial by Clarke et al., 46 patients were randomly 
allocated into two groups where one group received an 
injection of autologous dermal fibroblast suspended in 
autologous plasma and the other received autologous 
plasma only. At 6-month follow-up, the group treated with 
cell therapy had significantly improved Victorian Institute 
of Sport Assessment (VISA) scores compared to the plasma 
group. Only one patient from the treated group developed 
late tendon rupture requiring surgical intervention. 
Interestingly, the rare opportunity to perform a histological 
analysis of a cell-treated tendon post rupture revealed nor-
mally appearing tendon cells where degenerative features 
were expected.150 This indicates promising finding that the 
Table 4. Animal models using cell therapy and growth factors.
Study (author/
year/ref.)
Model (n number 
where available)
Type/site of study Transgene Cell type Results
Gulotta et al. 
(2011)138
Rats (60) Surgically 
transected 
supraspinatus 
tendon
Scleraxis via 
adenovirus
BMMSC Improvement of tendon 
attachment strength in treated 
group compared to control
Gulotta et al. 
(2011)139
Rats (60) In vitro and in vivo 
study; surgically 
transected 
supraspinatus 
tendon
BMP-13 via 
adenovirus
BMMSC No improvement of repair of 
rotator cuff injury demonstrated
Gulotta et al. 
(2010)140
Rats (60) In vivo study MT1-MMP via 
adenovirus
BMMSC Treated group had more 
fibrocartilages at insertion point, 
improved biomechanical strength 
compared with control
Schnabel et al. 
(2009)141
Horses (12) In vivo study; 
collagenase-induced 
bilateral superficial 
digital flexor 
tendinopathy
IGF-I gene BMMSCs No difference in expression of 
collagen types I and III, IGF-I, 
cartilage oligomeric matrix 
protein (COMP), matrix 
metalloproteinase-3 (MMP-3), 
matrix metalloproteinase-13 
(MMP-13), and aggrecanase-1 
(ADAMTS-4). Significantly 
improved tendon histological 
scores
Wang et al. 
(2005)142
Rhesus monkeys In vitro study BMP-12 via 
adenovirus
BMMSC MSCs successfully differentiate 
into tenocytes via transfection 
with BMP-12
Wang et al. 
(2005)143
Culture of rat 
intrasynovial 
tenocytes
In vitro study bFGF via 
adeno-AAV 
vectors
Tenocytes Increased level of expression 
of the bFGF and types I and III 
collagen genes
Uggen et al. 
(2005)128
Rats In vitro and in vivo 
studies; surgically 
transected rotator 
cuffs tendon
PDGF-β or 
IGF-1 via 
retrovirus
Tendon 
fibroblasts
In vitro: increased collagen 
synthesis for PDGF-β and 
IGF-1 treated cells; in vivo: 
demonstrated accelerated repair 
in the group with genetically 
modified cells
Wang et al. 
(2004)144
Culture of rat 
intrasynovial 
tenocytes
In vitro study VEGF or 
PDGF-β
Tenocytes Expression of the TGF-β gene 
increased significantly. No 
significant effect on expression 
of types I and III collagen genes 
compared to PDGF-β gene cells
Wang et al. 
(2004)145
Culture of rat 
intrasynovial 
tenocytes
In vitro study PDGF-β gene Tenocytes Levels of expression of the type 
I collagen gene and PDGF gene by 
tenocytes increased significantly
PDGF-β: platelet-derived growth factor β; VEGF: vascular endothelial growth factor; TGF-β: transforming growth factor β; IGF-1: insulin-like growth 
factor-1; bFGF: basic fibroblast growth factor; AAV: adeno-associated viral; BMMSC: bone marrow mesenchymal stem cells; BMP-12: bone morpho-
genetic protein 12; MT1-MMP: membrane type 1 matrix metalloproteinase.
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injected fibroblasts were able to differentiate successfully 
into tenocytes in vivo, producing a better histological repair 
of an injured tendon at microscopic level compared to the 
fibrosis and scarring that would have ensued if left to 
nature’s devices. Obaid et al. carried out a double-blind 
randomized controlled trial using dermal fibroblast com-
pared to a control group using local anesthetist infiltration 
and physiotherapy in 32 patients with Achilles tendinopa-
thy. Bilateral and unilateral involvement patient groups 
were analyzed separately for VISA and visual analog scale 
scoring at 6-month follow-up. The patients who had unilat-
eral Achilles tendinopathy showed significant improve-
ments in the scores compared to the control group. 
However, in the patient group with bilateral involvement, 
there was no significant difference detected. The author 
postulates that this may be a result of the small sample size 
in this group.151
In the trial performed by Ellera Gomes et al.,152 the 
infiltration of autologous bone marrow mononuclear cells 
prior surgery for management of operative rotator cuff 
tears was investigated. This study primarily demonstrated 
safe use of autologous cells in vivo in humans which may 
aid healing of tendon postoperatively after rupture. 
However, due to the lack of a control group, no significant 
improvement in functional outcome can be concluded 
from the study.
These five clinical trials were carried out in a nonran-
domized or double-blinded fashion due to the relative 
small number of patients recruited. Overall, results 
showed good response to treatment from the patient’s 
perspective and low rupture rates. There were no reported 
safety issues with the use of autologous cell therapy. 
However, more research is still required to accurately 
determine the safety and efficacy of the use of cell ther-
apy in tendon disease especially if stem cells are to be 
considered.
During the literature search for published clinical tri-
als in clinicaltrials.gov database, we found three ongoing 
clinical trials which are currently still recruiting patients 
for application of cell therapy in tendon diseases. This 
includes a double-blind randomized control trial held in 
the Netherlands using autologous tenocyte implantation 
in patients affected by chronic Achilles tendinopathy153 
and a nonrandomized pilot study in South Korea investi-
gating safety and efficacy of the use of allogeneic adi-
pose-derived MSCs in lateral epicondylitis.154 Another 
promising clinical trial in Spain involves the use of MSCs 
embedded in a construct (under the commercial name of 
OrthADAPT) for rotator cuff repairs which started in 
May 2010 and was scheduled to conclude in December 
2013.155 The scientific and medical circle will anticipate 
the future publications of these results as they will no 
doubt contribute significantly in the quest for successful 
clinical implementation of cell therapy in tendon 
injuries.
Discussion
Practical considerations: limitations and issues 
surrounding the use of cell therapy
There are several factors which affect the success of cell 
therapy procedures such as good cell–scaffold interaction, 
presence of cell adhesions on matrix surface, and adequate 
ECM production.40 Intact tendons have adequate vascular 
and nervous supply to maintain function; hence, effective 
revascularization and innervation in engineered tissues is 
key to viability and function in vivo.16
Several animal and clinical trials have highlighted the 
issue of effective dosage of implanted cells for optimal 
results in vivo. Timing of cell-based therapy between 
injury and treatment has been shown to have effect on the 
outcomes. Modulating the early stages of tendon healing is 
crucial in the treatment and outcomes of tendon injuries;156 
hence, the timing of implantation is important in the suc-
cess of treatment.59 Therefore, more comparative studies 
will need to be carried out to determine best cell source 
and treatment regimen.
Translatability of the characteristics of tendinopathy in 
animal subjects to human is also a potential problem that 
needs to be addressed. Animal models are not currently 
validated for defining tendinopathy in humans, which puts 
into question just how much we can gain from animal 
research alone.61 However, as we see increasing number of 
clinical trials being carried out internationally, the transfer-
ability and accuracy of such research will certainly become 
more evident with time.
Practically, researchers are also faced with the question 
of the accountability of the injected cells in relation to the 
regenerative findings in the tendon healing process. There 
needs to be careful interpretation of results as researchers 
need to take into account the local and systemic effects of 
cell therapy on the body. It is important to differentiate this 
from the potential effects of exogenous stem cells produc-
ing signaling molecules which may initiate migration of 
endogenous cells to site of repair. Therefore, future studies 
in this field ought to address the issue of tracking and dif-
ferentiating the effects of the exogenous cells.
The safety of stem cell–based treatment in the clinical 
setting is also of chief concern for all disciplines working in 
this field. Several studies have reported cases of ectopic 
bone formation in vivo;28,114,157 Harris et al.157 found ectopic 
bone formation in 28% of MSC-treated rabbit tendons in 
their study. This demonstrates that control variables are still 
not perfected, and further research is still required before 
clinical application with the use of MSCs. The use of stem 
cell also carries a risk of tumorigenesis which can result in 
cases of sarcoma and teratoma formation in vivo. Tasso et 
al.158 found sarcoma formation with the use of MSCs 
seeded in bioscaffolds in syngeneic and immunodeficient 
mice, raising the concern of immunogenic response that 
cell-based therapy can induce. In terms of safety issues 
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surrounding the culturing of MSCs in vitro, some literature 
have raised concerns of chromosomal abnormalities159,160 
and possible tumorigenicity161,162 that can result in in vitro 
expansion of MSCs. This triggered a recent review by the 
Cell Products Working Party and the Committee for 
Advanced Therapies in the European Medicines Agency in 
2013. In response to the need to tackle safety concerns, they 
organized a meeting with leading experts to discuss the safe 
use of MSC and to address the risk of inducing chromo-
somal abnormalities in culturing MSC. They have since 
published their review in a comprehensive article detailing 
their current recommendations.163
In conclusion, there is a need for more well-designed 
long-term studies with adequate controls and blinding 
measure and larger sample sizes to help accurately deter-
mine the overall effectiveness and safety of cell therapy in 
tendon disease.
The future
The prospect of widespread clinical use of cell therapy is 
becoming closer to reality with more studies demonstrating 
its effectiveness in restoring form and function. However, 
we are still faced with many challenges. Further research to 
help identify precise conditions to optimize tendon repair 
and improve success of cell therapy for tendon disease is 
crucial. In the future, more researchers will be seen com-
bining cell therapy with other tissue engineering techniques 
such as the use of growth factors, biomaterials, and gene 
therapy to help the complete regeneration of tendon tissues 
in vivo. Combining these bioengineering methods to act 
synergistically seems to be the most thorough and novel 
approach to facilitate the goal of returning normal function 
to a damaged tendon. Using a multidisciplinary scientific 
approach is likely to be the way forward for the successful 
implementation of functional tissue engineered tendon 
repair.164 Research into these methods is currently in its 
infancy, and we still have some way to go before such ther-
apies can be safely introduced into clinical trials.
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